128 related articles for article (PubMed ID: 32786924)
1. Thermal Control of Engineered T-cells.
Abedi MH; Lee J; Piraner DI; Shapiro MG
ACS Synth Biol; 2020 Aug; 9(8):1941-1950. PubMed ID: 32786924
[TBL] [Abstract][Full Text] [Related]
2. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
3. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors.
Morgan MA; Schambach A
Hum Gene Ther; 2018 Oct; 29(10):1083-1097. PubMed ID: 30156435
[TBL] [Abstract][Full Text] [Related]
5. Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines.
Kulemzin SV; Matvienko DA; Sabirov AH; Sokratyan AM; Chernikova DS; Belovezhets TN; Chikaev AN; Taranin AV; Gorchakov AA
BMC Med Genomics; 2019 Mar; 12(Suppl 2):44. PubMed ID: 30871576
[TBL] [Abstract][Full Text] [Related]
6. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
Hammill JA; Afsahi A; Bramson JL; Helsen CW
Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020
[TBL] [Abstract][Full Text] [Related]
7. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
8. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
9. Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry.
Xu C; Yin Y
Methods Mol Biol; 2020; 2108():159-165. PubMed ID: 31939179
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
12. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
Srivastava S; Riddell SR
J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
[TBL] [Abstract][Full Text] [Related]
14. [Next generation engineered T cells for cell therapy: from lymphoma to solid tumors].
Catros V
Med Sci (Paris); 2019 Apr; 35(4):316-326. PubMed ID: 31038109
[TBL] [Abstract][Full Text] [Related]
15. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP
Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241
[TBL] [Abstract][Full Text] [Related]
16. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
17. Paving New Roads for CARs.
Hyrenius-Wittsten A; Roybal KT
Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
[TBL] [Abstract][Full Text] [Related]
18. Engineering T cells for adoptive therapy: outsmarting the tumor.
Kunert A; Debets R
Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
[TBL] [Abstract][Full Text] [Related]
19. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
Posey AD; Schwab RD; Boesteanu AC; Steentoft C; Mandel U; Engels B; Stone JD; Madsen TD; Schreiber K; Haines KM; Cogdill AP; Chen TJ; Song D; Scholler J; Kranz DM; Feldman MD; Young R; Keith B; Schreiber H; Clausen H; Johnson LA; June CH
Immunity; 2016 Jun; 44(6):1444-54. PubMed ID: 27332733
[TBL] [Abstract][Full Text] [Related]
20. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".
Feldmann A; Arndt C; Bergmann R; Loff S; Cartellieri M; Bachmann D; Aliperta R; Hetzenecker M; Ludwig F; Albert S; Ziller-Walter P; Kegler A; Koristka S; Gärtner S; Schmitz M; Ehninger A; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2017 May; 8(19):31368-31385. PubMed ID: 28404896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
